Immix Biopharma, Inc. Common Stock (IMMX) is a publicly traded Healthcare sector company. As of July 21, 2026, IMMX trades at $9.50 with a market cap of $729.70M and a P/E ratio of -10.00. IMMX moved +8.81% today. Year to date, IMMX is +66.67%; over the trailing twelve months it is +196.30%. Its 52-week range spans $1.34 to $12.14. Analyst consensus is strong buy with an average price target of $20.25. Rallies surfaces IMMX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks hedge fund and 13F ownership for IMMX, including fund holders, share counts, and position changes when data is available.
| Metric | Value |
|---|---|
| Price | $9.50 |
| Market Cap | $729.70M |
| P/E Ratio | -10.00 |
| EPS | $-0.89 |
| Dividend Yield | 0.00% |
| 52-Week High | $12.14 |
| 52-Week Low | $1.34 |
| Volume | 1.11M |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-29.44M |
| Gross Margin | 0.00% |
4 analysts cover IMMX: 0 strong buy, 4 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $20.25.